
Key Points
- 01Moderna (MRNA) now targets 15%-25% revenue growth in 2026
- 02Q3 2026 revenue rose 29% to about $1.31 billion
- 03Company returned to profit with $162 million net income
- 04mRNA flu shot mFLUSIVA approved, with limited 2026-27 US launch
Outlook raised on strong quarter and new products
Moderna increased its 2026 revenue growth outlook to a range of 15% to 25%, up from prior guidance of up to 10%, after reporting stronger-than-expected third-quarter 2026 results. Management linked the higher guidance to the performance of newer vaccines and the expansion of the company’s geographic footprint.
Third-quarter 2026 revenue rose 29% year over year to about $1.31 billion, supported primarily by higher Covid-19 vaccine sales in international markets and deliveries under long-term government partnerships. Revenue totaled $780 million in the United States and $533 million in international markets.
Moderna returned to profitability in the quarter, reporting net income of $162 million compared with a net loss of $200 million a year earlier. Diluted earnings per share were $0.38, versus a loss of $0.51 per share in the prior-year period.
Vaccine portfolio gains traction
Chief Executive Officer Stéphane Bancel highlighted new product launches and diversification of geographies as key drivers of the quarter. He pointed to the full-year impact of Moderna’s next-generation mRNA Covid-19 vaccine, which received U.S. approval in May 2025, as a contributor to the stronger performance.
The company also advanced its respiratory franchise with the U.S. Food and Drug Administration’s August approval of its stand-alone flu vaccine, mFLUSIVA, for adults aged 50 and older. This product is Moderna’s fifth globally approved vaccine and the first mRNA-based seasonal influenza shot authorized in the United States.
Because flu vaccine contracts for the 2026–27 season had largely been completed before mFLUSIVA was cleared, Moderna plans a limited U.S. launch during that season. The company expects that timing effects will constrain near-term flu revenues even as it builds a broader respiratory portfolio.
Financial framework and balance sheet
Alongside the upgraded revenue outlook, Moderna set its 2026 research and development spending target at approximately $2.7 billion. The company also projected year-end 2026 cash and investments of about $8.1 billion to $8.3 billion, supported in part by net proceeds of about $2.6 billion from convertible note financing.
Management indicated that roughly half of 2026 revenue is expected to come from the United States and half from international markets. The company continues to pursue international partnerships, including multi-year agreements with governments, to support recurring vaccine demand and market expansion.
Oncology progress and pipeline setbacks
Beyond vaccines for respiratory diseases, Moderna reported late-stage data from its personalized cancer vaccine intismeran in combination with Keytruda in high-risk melanoma. The regimen reduced the risk of recurrence or death by 42% compared with Keytruda alone in the intention-to-treat population, with an even greater reduction observed after six months in a prespecified sensitivity analysis.
Moderna and its partner are preparing for potential regulatory submissions based on the melanoma data and are planning for a possible commercial launch, subject to regulatory approval. Additional oncology programs, including mRNA-4359 in melanoma and non-small cell lung cancer and mRNA-4203 in collaboration with Immatics, continue in clinical testing.
In contrast, the company’s norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success in a phase 3 interim analysis. Moderna does not plan to start an additional cohort this season and intends to discuss the future of the program with health authorities.
Key Takeaways
- 01Raising 2026 revenue growth guidance to 15%-25% signals confidence in Moderna (MRNA)’s newer vaccines and international strategy.
- 02The return to profitability and a projected cash balance above $8 billion give the company financial capacity to fund its pipeline.
- 03Regulatory progress for mFLUSIVA and strong melanoma data for intismeran deepen Moderna (MRNA)’s diversification beyond its initial Covid-19 franchise.
- 04Setbacks such as the norovirus trial outcome show ongoing pipeline risk even as headline results and guidance improve.
References
- https://www.cnbc.com/2026/11/06/moderna-mrna-earnings-q3-2026.html
- https://www.investing.com/news/stock-market-news/moderna-lifts-annual-revenue-forecast-on-strong-covid-vaccine-demand-overseas-5007491
- https://www.panabee.com/news/moderna-earnings-q3-2026
- https://www.stocktitan.net/news/MRNA/moderna-reports-third-quarter-2026-financial-results-and-provides-9kk4tzh724ed.html